Cigarette smoke-associated inflammation impairs bone remodeling through NFκB activation

Yi Lu1,2†, Yuanpu Peter Di3*,†, Ming Chang1†, Xin Huang1, Qiuyan Chen4, Ni Hong1, Beth A. Kahkonen3, Marissa E. Di3, Chunyan Yu5, Evan T. Keller5 and Jian Zhang1,2,6*

Abstract

Background: Cigarette smoking constitutes a major lifestyle risk factor for osteoporosis and hip fracture. It is reported to impair the outcome of many clinical procedures, such as wound infection treatment and fracture healing. Importantly, although several studies have already demonstrated the negative correlation between cigarette consume and impaired bone homeostasis, there is still a poor understanding of how does smoking affect bone health, due to the lack of an adequately designed animal model. Our goal was to determine that cigarette smoke exposure impairs the dynamic bone remodeling process through induction of bone resorption and inhibition of bone formation.

Methods: We developed cigarette smoke exposure protocols exposing mice to environmental smoking for 10 days or 3 months to determine acute and chronic smoke exposure effects. We used these models, to demonstrate the effect of smoking exposure on the cellular and molecular changes of bone remodeling and correlate these early alterations with subsequent bone structure changes measured by microCT and pQCT. We examined the bone phenotype alterations in vivo and ex vivo in the acute and chronic smoke exposure mice by measuring bone mineral density and bone histomorphometry. Further, we measured osteoclast and osteoblast differentiation gene expression levels in each group. The function changes of osteoclast or osteoblast were evaluated.

Results: Smoke exposure caused a significant imbalance between bone resorption and bone formation. A 10-day exposure to cigarette smoke sufficiently and effectively induced osteoclast activity, leading to the inhibition of osteoblast differentiation, although it did not immediately alter bone structure as demonstrated in mice exposed to smoke for 3 months. Cigarette smoke exposure also induced DNA-binding activity of nuclear factor kappaB (NFκB) in osteoclasts, which subsequently gave rise to changes in bone remodeling-related gene expression.

Conclusions: Our findings suggest that smoke exposure induces RANKL activation-mediated by NFκB, which could be a "smoke sensor" for bone remodeling.

Keywords: Cigarette smoking, Inflammation, Bone remodeling, NFκB

Introduction

Cigarette smoking (CS) has been identified as a key contributing factor in the development of a variety of fatal and debilitating disorders, including respiratory and cardiovascular diseases. It is also confirmed that CS contributes to delayed bone union during fracture
healing [1]. Epidemiological evidence indicates that CS enhances bone loss and fragility fracture incidence, making it a major lifestyle risk factor for osteoporosis. The association between CS and fracture has been reported in both men and women [2–5]. However, the underlying mechanisms of how CS negatively affects bone are not completely known, partially obfuscated by the influence of smoking on sex hormones in both genders [6]. Specifically, decreased bone mineral density (BMD) has been shown to correlate with increased fracture risk [7–10]. The persistent evidence of higher levels of bone resorption markers in smokers [11] and reduced serum osteocalcin levels in early postmenopausal women smokers [12, 13] suggests that an imbalance in the bone remodeling process arises in smoking individuals.

Normal bone development and maintenance are sustained through a balanced communication between osteoclasts and osteoblasts, cells responsible for bone resorption and bone formation, respectively, in accordance with mechanical demands that keep the shape and strength of bone within strict limits [14]. This dynamic balance is coordinated through cell–cell contact, and also tightly controlled by a variety of signals including hormones, cytokines, and mechanical stimuli [15]. In this way, intercellular communications initiate and coordinate the bone remodeling cycle. Inversely, the imbalance of bone formation and bone resorption leads to pathological bone loss, which subsequently results in bone-related diseases such as osteoporosis [16].

Smoking is not only harmful to an individual’s own health but also surrounding subjects. Secondhand smoke (SHS) is an important risk factor for non-smoker women suffering from lung cancer [17]. Furthermore, CS also increased the risk of hip fracture in smokers compared to never smokers [4]. However, supporting evidence in animal models to directly link cigarette smoke exposure with dynamic changes in bone remodeling is still lacking. Specifically, the cellular and molecular mechanisms responsible for the adverse effects of both CS and SHS on bone remain poorly understood due to lack of suitable animal experimental models. Despite the suggestion that smoking has a direct adverse effect on skeletal remodeling and bone cells, the observation of impaired bone formation was during nicotine exposure in an animal model, rather than showing a direct causal association with using cigarette smoke, which contains complex chemical mixtures of more than nicotine alone. Recently, there is a report that showed in an in vivo mouse model that animals exposed for 6 months to cigarette smoke has dramatically affect bone integrity and biomechanical properties by using the ApoE knockout mouse model [18].

The aim of the present study was to explore the effect of CS on the dynamic balance between bone resorption and bone formation using mouse models systematically exposed to a smoking environment. We compared smoking-associated defects of animals with an exposure time of 10 days and 3 months using two protocols to compare the effects of acute and chronic smoke exposure on animals, respectively. Osteoblast formation and bone resorption were investigated among smoke and non-smoke (filtered air) exposed animals. Biochemical analyses using cigarette smoke extract (CSE) in vitro further identified the DNA-binding activity of transcription factors regulating changes in bone remodeling-related gene expression.

**Materials and methods**

**Reagents and antibodies**

Research-grade 3R4F cigarettes were obtained from the University of Kentucky Tobacco Research and Development Center (Lexington, KY, USA). Recombinant human M-CSF (rhM-CSF) and rhRANKL were purchased from R & D Systems (Minneapolis, MN, USA). NFκB P65 antibodies and Cyclin D1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). QNZ (EVP4593) was purchased from Selleckchem (Houston, TX, USA). All chemical reagents were purchased from Sigma (St. Louis, MO, USA).

**Mice**

Eight-week-old Fv/n mice (The Jackson Laboratory, Bar Harbor, ME, USA) were housed under pathogen-free conditions in accordance with NIH guidelines. All animal experiments were conducted in accordance with approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. The mice were treated with whole body cigarette smoke exposure in a smoking chamber with an average monitored smoke exposure concentration of $100.3 \pm 7.2 $ mg/m$^3$ total smoke particulate (TSP). In protocol 1, the chronic smoke exposure model, the mice (n $= 20$) were assigned into two groups: non-smoke and smoke. The mice in the smoke group were exposed to cigarette smoke for 6 h/day and 5 days/week for 12 weeks. In protocol 2, the acute smoke exposure model, the mice were divided into 4 groups: non-smoke, smoke, non-smoke with lipopolysaccharide (LPS), and smoke with LPS (n $= 12–14$/group). The smoke mice were exposed for 6 h/day and 5 days/week for 2 consecutive weeks, and the LPS mice were treated with 0.2 mg/kg body weight/mouse via intranasal instillation. The mice were allowed to grow for the indicated time until sacrifice. Evidence of bone changes caused by smoke exposure was evaluated using a micro computed tomography (microCT), peripheral quantitative...
computed tomography (pQCT), histology, and bone histomorphometry.

**microCT analysis**
The fifth lumbar vertebrae of the mice were fixed in 3.7% formaldehyde and used for 3D microCT analysis. First, 2D CT horizontal slices of the lumbar were obtained with a Scanco vivaCT40 (Scanco Medical, Bassersdorf, Switzerland). The thickness of the slices was 21 μm. Three-dimensional images were reconstructed using software provided by Scanco. The trabecular bone was measured in the tissue area. Parameters analyzed from 3D images included the ratio of trabecular bone volume and total bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp).

**Bone mineral density analysis**
Tibiae from all animals were measured for bone mineral density (BMD) using pQCT (Stratec, Dundas, Ontario, CA). pQCT scans from three slices of the proximal metaphysis region were performed to obtain total bone mineral densities and trabecular bone mineral densities.

**Histopathology and bone histomorphometry**
Histopathology was performed as described previously [19]. Briefly, bone specimens (tibiae) were fixed in 10% formalin for 24 h, then decalcified using 10% EDTA for 6 days. The specimens were then paraffin-embedded, sectioned (4 μm), and stained with hematoxylin and eosin (H&E) to assess histology. Histomorphometric analysis was performed on H&E stained sections and a variety of parameters were quantified using Bioquant Osteo II (Bioquant Image Analysis Corp, Nashville, TN) as previously reported. The terminology used is as recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research. The sections were used for tartrate-resistant acid phosphatase (TRAP) staining (acid phosphatase kit, model 387-A; Sigma Diagnostics, Livonia, MI, USA). For TRAP staining, the specimens were stained with acid phosphatase and tartrate solution for 1 h at 37 °C. The area of TRAP positivity was quantified using Bioquant Osteo II software. Four discontinuous random regions of interest were examined within each tibia. TRAP-positive cells were counted along the endocortical bone surfaces. The number of TRAP-positive cells is reported as osteoclasts/mm. Osteoblasts were identified as cuboidal-shaped cells on the bone surface. The number of osteoblasts/mm bone was calculated by averaging the numbers of osteoblasts in five randomly chosen fields.

**Preparation of CSE**
Research-grade 3R4F cigarettes were smoked using a peristaltic pump (VWR International, West Chester, PA, USA) [20]. Briefly, each cigarette was smoked for 10 min, until a 17 mm butt remained. Four cigarettes were bubbled through 40 ml of cell growth medium, and this solution, regarded as 100% strength CSE, was adjusted to a pH of 7.4. Following preparation of CSE, the solution was filtered through 0.2-μm filters immediately prior to treat cells. The highest concentrations of CSE used in our experiments were chosen such that cellular viability was no less than 95% of that in control cells cultured in the absence of CSE.

**Cell culture**
MC3T3-E1 subclonal 4 (MC-4) cells were kindly provided by Dr. Guozhi Xiao (University of Pittsburgh, Pittsburgh, PA, USA). MC-4 cells were pre-osteoblast, expressing osteoblast phenotypic marker genes and mineralizing only after growth in AA (ascorbic acid)-containing medium [21]. MC-4 cells were maintained in AA-free α-MEM (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.

**Mouse bone marrow mononuclear cell (MBMC) culture**
Primary mouse bone marrow cells were obtained by flushing femora from 8-week old Fvbn mice or from the mice at the end of treatments. The bone marrow cells were incubated in α-MEM medium (Invitrogen, Carlsbad, CA) with 20% FBS (HyClone, Pittsburgh, PA, USA) and 1% penicillin/streptomycin (Invitrogen) overnight at 37 °C in 100-mm tissue culture plates to allow for separation of non-adherent and adherent cells.

**Osteoclast formation and bone resorption assay**
Osteoclast formation assays were performed by culturing 1 × 10^5/well non-adherent bone marrow cells in 96-well plates in 0.1 ml of α-MEM with 10% FBS for 7 days. Cells were incubated with recombinant mouse M-CSF (10 ng/ml), RANKL (50 ng/ml), and CSE at concentrations indicated. Half of the media was changed at days 4 and 7. After 10 days of culture, the cells were fixed with 2% formaldehyde and stained with the K-ASSAY TRAP staining kit (Kamiya Biomedical, Seattle, WA). Positively stained cells that contained 3 or more nuclei were counted as osteoclast-like multinucleated cells. Analysis of all osteoclast formation experiments included data from 3 independent experiments.

To perform the bone resorption pit assay, murine non-adherent bone marrow cells (1 × 10^5/well) were seeded on dentin slices in 96-well plates and treated as above.
After 2 weeks of culture, osteoclasts on dentin slices were confirmed by TRAP staining, and bone resorption lacunae were stained with hematoxylin. The mean area of resorption was determined microscopically with SPOT software (Diagnostic Instruments, Inc. Sterling Heights, MI).

Osteoblast differentiation
MC-4 cells or primary murine bone marrow stromal cells (mBMSC) were plated in 6-well plates at 5 x 10⁴ cells/cm² and incubated in differentiation medium, which contains growth medium and ascorbic acid (AA, 50 μg/ml). They were treated as indicated for 5–7 days. Then cells were provided with inorganic phosphate for the mineralization assay, or cell lysates were collected for detection of alkaline phosphatase (ALP) activity, and the supernatants were applied for measurement of TNFα levels, or total RNA was extracted for determination of osteoblast differentiation marker gene expression levels. To confirm CSE induced NF-κB pathway activation, mBMSCs were treated with QNZ, NF-κB inhibitor, at 1–20 nM w/o 1% CSE and the supernatant was collected and TNFα levels were measured by ELISA.

Mineralization assay
Mineralization analysis was performed by von Kossa staining and/or Alizarin red (AR-S) staining. Briefly, for von Kossa staining, the cells were rinsed once with PBS, fixed with 95% ethanol for 15 min at 37 °C, and then serially hydrated in 80%, 50%, 20% ethanol to distilled water (ddH₂O). The water was removed, a 5% silver nitrate solution was added to each well, and the plate was covered with Al foil and incubated for 1 h at 37 °C. After the silver nitrate solution was removed, the plate was rinsed twice with ddH₂O, exposed to bright light for at least 30 min, then rinsed with water, dehydrated in 50%, 95%, 100% ethanol, and dried for image analysis. For alizarin red (AR-S) staining, the cells were rinsed once with PBS, fixed with cold 70% ethanol for 60 min, and rinsed 3 times with ddH₂O to remove ethanol completely. The cells were then stained with 40 mM AR-S (pH 4.2) at RT for 15 min with rotation on a shaker. After that, cells were rinsed with ddH₂O five times to remove unbound AR-S and one time with PBS for 15 min to further reduce non-specific staining. Photographs were then taken at this point. To quantify the AR-S stain, 10% cetylpyridinium chloride (CPC) was added to the wells at RT for 30 min with shaking. Aliquots of these AR-S extracts were taken, diluted in 10% CPC solution, and the concentrations were determined by absorbance measurement at 562 nm on a 96-well multiple plate reader.

Quantitative real-time RT-PCR
Total RNA was extracted from the differentiated osteoclast, osteoblast, or MC-4 cells at the end of treatments using TRizol reagent (Life Technologies, Gaithersburg, MD) according to the manufacturer’s protocol. Reverse transcription (RT) was performed using 2 μg of total RNA and 100 pmol of random hexamers (Applied Biosystems, Foster, CA) in a total volume of 20 μl containing 12.5 U MultiScribe reverse transcriptase (Applied Biosystems) according to the manufacturer’s instruction. PCR was performed on iCycler iQ multicolor real-time PCR detection system (Bio-Rad, Hercules, CA) using SYBR Green PCR kit (Applied Biosystem). Primer sequences used in this study are listed in Table 1. All the amplifications were performed as follows: initial denaturation at 95°C for 10 min followed by 45 cycles of 95°C for 15 s and 60°C for 60 s. Melting curve analysis was performed to evaluate the purity of the PCR products. Triplicate samples were run for each primer set. The target gene expression was calculated relative to GAPDH (a housekeeping control gene) using the ΔCT method as previously described [22].

Nuclear protein extraction
Nuclear protein extractions from the cells were prepared by using Nuclear Extract Kit (Active Motif, Carlsbad, CA) according to the manufacturer’s protocol. Briefly, the cells were washed twice with ice-cold PBS and phosphatase inhibitors. Cells were removed with a cell lifter by gentle scraping, and cell pellets were collected

| Gene | Forward primer (5’ to 3’) | Reverse primer (5’ to 3’) |
|------|---------------------------|-------------------------|
| Cat K| GTGTTGGTGGTGTTGGGCTATG    | GCAGCGGCTTGTCTTATCTCC   |
| TRAP | CACCTGAGATTGTGGCGCTG      | CGGTCTGCGGATCTTCTTGT    |
| CTR  | GGGCGACTCTACGTGCTCCTTG    | GATTCGGTGGTCTGTAAGTG    |
| Runx2| TGGCTTGGAAGGTCAGGGT    | TGGTTTCTTAGGGCGTGTGGA   |
| OCN  | TAGTGAACAGACTCCGGC   GCTA | TGAGCCGCTGCTTCAAGCCAT   |
| Col I| CTGACTCGAAGAGGCGAAGAG    | GCACAGCGGCTGAGTAGG      |
| OSX  | AGAGGTTCACCTCCTCGCTTG     | TTGCTCAAGGCTGCTTCTCG    |
| BSP  | AGAGGGAAAGAAAAATGAGA     | GCTTCTCTGCCGTGTCTCC     |
| OPN  | CCA ATG AAA GCC ATG ACC A | CGT CAG ATT CAT CCG AGT CCA C  |
| OPG  | TACCTGGAGATCGAATTC TGCTT | CCATGGACATTTTTTGCAA A |
| RANKL| GAAACCTACAGGCCCTCTC TCTTG | GCACCTGAAATACCTCCTCAATC |
| GAPDH| CGTGCCAGCCCTGCTCC GTAGA | CTGCAAAATGGGACGCCCCTG CTGAC |
after centrifugation for 5 min at 500g. The pellets were resuspended in 1× hypotonic buffer and centrifuged at 14,000g for 30 s at 4 °C. From the resuspension, the supernatant was collected as the cytoplasmic fraction. The insoluble pellet, which contained nuclei, was resuspended in 50 µl Complete Lysis Buffer and vortexed for 15 s, incubated and suspended for 30 min on ice on a rocking platform set at 150 rpm, then vortexed again for 30 s and centrifuged at 14,000g for 20 min at 4 °C. The supernatant (nuclear fraction) was aliquoted into precooled tubes stored at -80 °C. Protein concentration was determined with the BCA protein assay kit (Pierce, Rockford, IL).

**Electrophoretic mobility shift assays (EMSA)**

Detection of protein–oligonucleotide complexes was performed with an EMSA gel-shift kit (Active Motif). Briefly, NF-kB oligonucleotide probes (Santa Cruz Biotechnology) were labeled with [32P]ATP at 50,000 cpm/ng using T4 polynucleotide kinase. Nuclear extracts (5 µg) were incubated with 1 µg of poly(deoxyinosinic–deoxycytidylic acid), gel shift reaction buffer [10 mM Tris (pH 7.5), 50 mM NaCl, 1 mM DTT, 1 mM EDTA, and 5% glycerol], and 0.5 ng of labeled oligonucleotide probes for 30 min at room temperature. For supershifts with p65 antibody or Cyclin D1 antibody, nuclear extracts were pre-incubated with 1 µl of p65 antibody or cyclin D1 antibody (Santa Cruz Biotechnology) for 15 min at room temperature before the addition of binding buffer and probe. DNA–protein complexes were resolved by electrophoresis through a 4% polyacrylamide gel containing 50 mM Tris (pH 7.5), 0.38 M glycine, and 2 mM EDTA. The gel was then dried and visualized by autoradiography.

**ELISA**

Quantikine Mouse TNFa/TNFSF1A Immunoassay kits were purchased from R & D Systems (Minneapolis, MN). The levels of TNFα in bone marrow plasma collected from both animal models, and in the supernatants collected from CSE-treated BMSC cells, were measured using the ELISA kit according to the manufacturer’s instructions. The sensitivity of this assay is 0.51 pg/ml.

**Alkaline phosphatase (ALP) activity**

The cell lysates were harvested in 1× Passive Lysis Buffer (Promega, Madison, WI) and clarified by centrifugation at 13,000g for 20 min at 4°C. Five microliters of cell lysate was added to each well (96-well plate) containing 150 µl p-nitrophenyl phosphate (pNPP) (Sigma) at 37 °C for 10–60 min depending on the level of ALP activity in the extracts. ALP activity was determined by absorbance measurement at 405 nm on a 96-well plate reader. ALP activity was normalized to total protein.

**Statistics**

Statistical significance was determined for multivariate comparisons using ANOVA and Fisher’s probable least significant difference for post hoc analysis. Student’s t test was used for bivariate analyses. Statistical significance was determined as P < 0.05. Statistical calculations were performed using Statview software (Abacus Concepts, Berkeley, CA).

**Results**

**Study design**

In this study, we hypothesize that cigarette smoke exposure impairs the dynamic bone remodeling process through induction of bone resorption and inhibition of bone formation. The overall aims of this study were to (i) investigate smoke exposure impairs the bone remodeling through induction of bone resorption and inhibition of bone formation in vivo, (ii) determine the mechanisms of how smoke exposure affects bone remodeling in vitro at both cellular and molecular levels. To address these aims, we used in vivo animal models, to demonstrate the effect of smoking exposure on the cellular and molecular changes of bone remodeling and correlate these early alterations with subsequent bone structure changes measured by microCT and pQCT. We established smoking mice model, including 3-month smoking mice to mimic chronic smoke exposure, and 10-day smoking mice to mimic the acute smoke exposure. We examined the bone phenotype alterations in vivo and ex vivo in the acute and chronic smoke exposure mice by measuring bone mineral density and bone histomorphometry. Next, we measured osteoclast and osteoblast differentiation gene expression levels in each group. The function changes of osteoclast or osteoblast were evaluated. Finally, we tested cigarette smoke induces DNA-binding activity of NFkB using cigarette smoke extract (CSE). In all experiments, the sample size was determined by previous experience of the statistical variance encountered, statistical calculations were made based on the following criteria: power of 80% and a significance level < 0.05.

**Chronic smoke exposure enhances osteoclast maturation and bone resorption-related gene expression**

For all the experiments, 8-week-old Fvb/n mice were exposed to whole body cigarette smoke in a smoking chamber. To study the effect of smoke exposure on bone development, animals were passively exposed to cigarette smoke for 6 h/day and 5 days/week for 12 weeks in protocol 1. Based on previous studies suggesting that the spine is more severely affected by smoking than other sites [23, 24], as spine contains predominantly trabecular bone, bone structural changes were initially captured by microCT in lumbar spine L5. Smoke exposure
Gene expression of bone resorption markers including CatK, TRAP, and CTR were greatly elevated in the non-adherent bone marrow cells from the smoke-exposed animals (Fig. 2c). In addition, smoke exposure combined with LPS administration further enhanced the gene expression of those same markers compared to either the smoke-exposed animals without LPS administration or the non-smoke-exposed animals with LPS administration (Fig. 2c).

We also explored the effect of short-term smoke exposure on osteoclastogenesis. Non-adherent bone marrow cells were isolated from the aforementioned experimental mice and tested for osteoclast formation. Smoke exposure significantly induced in vitro osteoclast formation in the cells isolated from smoke-exposed animals, compared...
to those from the non-smoke-exposed animals (Fig. 2d, e). LPS treatment was observed to amplify the effects of smoke exposure. This suggests that under inflammatory conditions, smoke exposure may contribute to enhanced osteoclast formation. In support of the findings described above, LPS and nicotine were reported to stimulate osteoclast formation in osteoclast precursor RAW 264.7 cells [25] and primary non-adherent bone marrow cells through direct enhancement of receptor activator of NF-kappaB ligand (RANKL) expression [27] and suppression of Osteoprotegerin (OPG) expression [28, 29]. A decoy receptor homolog for RANKL, OPG inhibits receptor
activator of NF-kappaB (RANK) by binding to RANKL. OPG is thus tightly involved in regulating NF-κB activation [30]. Continuous exposure to cigarette smoke also increased the number of inflammatory cells, including alveolar macrophages, as well as led to the recruitment of neutrophils, which are commonly associated with LPS-induced inflammation [31]. Taken together, our results suggest that adverse effects on bone may occur rapidly and the underlying cellular and molecular changes may precede the measurable bone structural alterations.

Smoking exposure inhibits osteoblast differentiation and activity

To investigate the effects of smoke exposure on osteoblast differentiation, the number of osteoblasts on the bone surface in tibiae was quantified by histomorphometry. We found that in both animal protocols, smoke exposure failed to alter the number of osteoblasts in the animals (Figs. 3a and 4a). However, at the cellular and molecular levels, in vitro osteoblast differentiation and bone mineralization were inhibited in the smoke-exposed animals compared to the non-smoke-exposed animals, as measured by both in vitro silver nitrate (von Kossa) and Alizarin Red-S (AR-S) staining (Figs. 3b and 4b).

Next, we performed real-time RT-PCR to determine the gene expression of osteoblast differentiation markers runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), type I collagen (Col I), osterix (OSX), bone sialoprotein (BSP), and osteopontin (OPN) using RNA isolated from these cells. Smoke exposure significantly reduced expression levels of RUNX2, OCN, Col I, OSX and BSP, except OPN (Figs. 3c and 4c). ALP activity in the cell lysates from the smoke-exposed mice was significantly inhibited compared to that of the non-smoke-exposed animals (Figs. 3d and 4d). Smoke exposure reduced the ratio of OPG/RANKL in these cells (Figs. 3e and 4e). Due to technical shortcomings, we were not able to measure the in vivo bone formation rate in this study, but nevertheless, our results clearly suggest that smoke exposure inhibited osteoblast differentiation and bone mineralization in vitro. Similar to results from protocol 2 settings, additive effects of smoke exposure with LPS administration were also observed using the indicated parameters (Fig. 4). These results indicate that under inflammatory conditions, smoke exposure may further enhance the inhibitory effect on osteoblast differentiation and bone mineralization.

Cigarette smoke extract (CSE) impairs bone remodeling mediated by the NFκB pathway

Studies of adverse effects of cigarette smoke exposure on bone have been made challenging by the properties of cigarette smoke, which is composed of over 4,000 different chemicals, including 43 known carcinogenic compounds and 400 other toxins. For example, polycyclic aromatic hydrocarbons present in cigarette smoke were shown to cause loss of bone mass and bone strength in rats [32]. Therefore, CSE was chosen in the present study to investigate the mechanisms of smoke exposure’s adverse effects on bone. Surprisingly, CSE induced TRAP-positive, multinucleated osteoclast-like cell formation in non-adherent bone marrow cells (Fig. 5a). Consistent with this result, CSE also induced the mRNA expressions of CatK, TRAP, and CTR (Fig. 5b). In MC3T3 cells (a commonly used murine osteoblast cell line) and murine bone marrow adherent cells, CSE significantly inhibited bone mineralization in vitro (Fig. 5c). At the molecular level, the OPG/RANKL ratio of mRNA expression was decreased dose-dependently in both cells (Fig. 5d).

To dispel the possibility that this induction of osteoclast differentiation and inhibition of osteoblast differentiation was solely the result of induction of inflammatory mediators in the bone marrow, we measured TNFα levels in the bone marrow adherent cells treated with CSE at different concentrations. CSE dose-dependently induced TNFα levels (Fig. 5a). The levels of TNFα in bone marrow plasma were significantly higher in the smoke-exposed animals than in the non-smoke-exposed animals (Fig. 6b). QNZ significantly inhibited TNFα production dose dependently (Fig. 6c). The involvement of NFκB was further demonstrated by NFκB inhibition in cells treated with CSE. These results suggest that TNFα could be one of the key mediators in the bone remodeling process altered by smoke exposure.

Aiming to identify the DNA binding activity of CSE-regulated transcriptional factors, we tested the subunits p65 and cyclin D1 by gel-shift assay. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1 [33]. We observed a shift due to the formation of the p65-NFκB complex, whereas no binding could be detected between the downstream target cyclin D1 and NFκB, indicating that CSE affects NFκB signaling through complex formation (Fig. 6d). We also investigated the effects of smoking on the NFκB and AP-1 signaling pathways. Smoke exposure clearly induced NFκB expression in smoke-exposed animals compared to non-smoke-exposed animals, whereas no effect on AP-1 expression was detectable by gel-shift assay (Fig. 6e). These results distinctly indicate that smoke exposure induced RANKL activation, which is mediated by NFκB. Therefore, we propose that NFκB could be a “smoke-sensor” in bone cells.
Discussion

The study intended to provide an in vivo mouse model of acute and chronic second-hand exposure to cigarette smoke. In particular, we performed a descriptive approach into the negative role of cigarette smoke induce inflammation on bone homeostasis. In the US, the total economic cost of smoking is more than $300 billion per year. According to the U.S. Department of Health and Human Services, this includes nearly $170 billion in direct medical care for adults, as well as more than $156

Fig. 3 Chronic cigarette smoke exposure inhibited bone mineralization and downregulated the gene expression of osteoblast differentiation markers. a Smoke exposure did not alter the number of osteoblasts on bone interface measured by histomorphometry in the protocol 1 mice model. b BMSCs were seeded at $5 \times 10^4$ cells/cm$^2$ in 6-well plates and given differentiation medium for 10 days. Inorganic phosphate (5 mM) was added to the culture medium for another 4 days for mineralization assays. The capacity of bone mineralization was measured by von Kossa staining and alizarin red staining. c Gene expression of osteoblast differentiation markers including Runx2, OCN, Col I, OSX, BSP and OPN was determined by real-time RT-PCR. Levels of Runx2, OCN, Col I, OSX, BSP and OPN mRNA were normalized to GAPDH. d ALP activity was normalized to total protein. e OPG and RANKL gene expression in the osteoblasts were examined by quantitative RT-PCR. The ratio of OPG to RANKL is illustrated. Data are representative of three independent experiments. Data are presented as the mean±SD from triplicates. *P<0.05 compared to non-smoke group; **P<0.001 compared to non-smoke group
billion in lost productivity due to premature death and exposure to SHS. Smoking decreases life expectancy [34] and has been confirmed to be a causative factor in the acquisition of genetic lesions [35]. In the current study, we observed smoke exposure causing a significant imbalance between bone formation and bone resorption in both mouse models that were exposed to cigarette smoke for 10 days or 3 months. Ten-day smoke exposure efficiently induced osteoclast activity, inhibited osteoblast differentiation, and altered bone remodeling-related gene expression levels, although it did not transform the bone structure as drastically as their 3-month smoke exposure counterparts. Zhu, Sheng et al. reported recently (2021), they found similar results with our in vitro studies that bisphosphonates were able to reduce CSE-induced osteoporotic alternations using co-culture system [36].

The mechanisms by which smoking affects the skeleton may include both direct and indirect effects [37]. In an animal study, nicotine was shown to inhibit bone formation. In particular, a high concentration of nicotine...
profoundly inhibits oxidative metabolism and collagen synthesis in cultured chick bones [38]. In another study, a significant reduction of BMD was observed in nicotine-treated male mice and rats compared to animals without nicotine administration [39]. In consistence with our findings, there are a few groups reported in an in vivo mouse model that animals exposed for 6 months to cigarette smoke has dramatically affect bone integrity.
and biomechanical properties [18, 40]. Based on a study of twin pairs discordant for cigarette smoking, women consuming one pack of cigarettes per day throughout life will have 5–8% less bone than non-smokers by the age of menopause [23]. Other researchers have reported 5–10% less bone and reduced protective effects of nutritional calcium in postmenopausal smokers than in nonsmokers [2, 41]. Of note, the duration of smoke exposure was negatively associated with BMD at the total hip, femoral neck, lumbar spine and total body in premenopausal women [42], confirming that postmenopausal women who smoke are at increased risk for osteoporosis. A cohort study suggests that compared with never smokers, current male cigarette smokers have an increased risk of hip fracture [4]. In the current study, we reported an approximate 24% decrease in bone volume in vertebrae and 23% decrease in trabecular BMD in tibiae of 3-month smoke-exposed animals. These profound changes found in mice were possibly due in part to the duration and dose of smoke exposure chosen in our protocols.

Tobacco smoke is a complex mixture of chemicals, each of which with the potential to act through different signal cascades, leading to the regulation of distinct transcriptional factors, such as NFκB, and subsequent
alterations in gene expression [31]. In this study, we showed that activation of NFκB signaling pathways in bone cells by tobacco smoke exposure may be involved in the activation of resorption-induced genes such as RANKL, suggesting a potential mechanism for tobacco smoke-induced RANKL gene expression.

Given these changes in mRNA expression, we were interested in understanding whether the disparities arise from the alteration of mRNA transcription or translation. Studies towards a molecular understanding of inflammatory bone diseases have been highly successful from both an immunological and bone-centered perspective. The results of these studies led to the identification of several signaling pathways causally involved in inflammatory bone loss. Induction of RANKL signals by activated T cells and subsequent activation of the key transcriptional factors Fos/activator protein (AP-1), NFκB, and NF for activation of T cells c1 (NFATc1) are central to the signaling networks that to osteoclast-mediated bone loss [43].

Our data suggest that smoke exposure may also have a direct effect on bone. In support of our findings, it has been reported that in an in vivo mouse model, 2 weeks of smoke exposure stimulated the bone marrow cells and increased the size of the mitotic and postmitotic pools of polymorphonuclear leukocytes [44]. Mice exposed to cigarette smoke for three weeks exhibit loss of bone marrow B cells at the Pro-B-to-pre-B cell transition, with a largely reversed outcome after cessation of smoking 6 weeks [45]. Smoke exposure in immature rats significantly compromised bone health, leading to weaker bone [46]. There are other possible mechanisms for skeletal damage induced by smoking. It has been suggested that cigarette smoke may damage the blood supply and thus contribute to diminished bone strength [47]. In addition, cigarette smoke has been widely suggested to impact a broad range of immune functions [48, 49]. Finally, in support of our findings, Aspera-Werz, Romina et al. recently reported that extracts from conventional cigarettes significantly reduced the ALP activity and matrix mineralization at low concentrations [50].

In a prospective population-based cohort study of older men, people who stopped smoking have a significantly lower risk of hip fracture, at about 50%, during the first 10 years after stopping smoking [4, 51]. A decreased impact of smoking on the risk of hip fracture was also observed among women after cessation of smoking for more than 10 years [5]. Smoking cessation decreases N-terminal collagen cross-links (NTx) in postmenopausal women [52]. Additionally, smoking cessation is indicated as a preventive method and an effective measure to improve high-density lipoprotein functions in smokers suffering from coronary artery disease [53]. These studies suggest that the adverse effects of smoking are partially reversible. In future studies, it would be a high priority to further investigate whether the imbalance of bone remodeling caused by smoke exposure is reversible using a smoke cessation model.

We are cautious as to note that, in the current study, animal models are not completely replicate models of human cigarette smoking. In reality, smokers puff and then inhale in amounts that vary from moment to moment, and the amount drawn into the lungs differs from time to time, thus deviating from “standardized” machines used in animal experiments [54]. Other limitations for this report may include: a, the degree to which the particular concentrations and durations of smoke exposure used are biologically relevant; b, the use of CSE. CSE is advantageous in that it contains all the compounds inhaled by smokers, but due to the complexity of CSE, it is difficult to pinpoint which component mediates a specific effect. Nevertheless, we have begun to uncover the mechanisms of smoke exposure's effects on bone remodeling.

### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12967-021-02836-z.

---

**Abbreviations**

- microCT: Micro computed tomography; pQCT: Peripheral quantitative computed tomography; NFκB: Nuclear factor kappaB; CS: Cigarette smoking; SHS: Second hand smoke; CSE: Cigarette smoke extract; TSP: Total smoke particulate; LPS: Lipopolysaccharide; BMD: Bone mineral density; AA: Ascorbic acid; TRAP: Tartrate-resistant acid phosphatase, ALP: Alkaline phosphatase; CatK: Cathepsin K; CTR: Calcitonin receptor; OPG: Osteoprotegerin; RUNX2: Runx-related transcription factor 2; OCN: Osteocalcin; Col I: Type I collagen; OSX: Osterix; BSP: Bone sialoprotein; OPN: Osteopontin.

---

**Additional file 1: Fig. S1**: Ten-day smoke exposure did not significantly alter the bone structure in vivo. A. The parameters of bone phenotypes were measured by microCT in 15 B. Bone mineral density (BMD) was determined by pQCT in the tibia.

**Acknowledgements**

We thank helpful discussion from Dr. G. David Roodman and technical assistance from Mr. Ken Patrene and Dr. Xia Liu. We thank Dr. Guozhi Xiao for providing MC-4 cells.

**Authors’ contributions**

- YL, YPD, MC, QC, ETK, and JZ designed the study and performed experiments;
- XH, QC, BAK, MED, and CY performed in vivo-related assays; YL, YPD, MC, and JZ conducted data analysis; YL, YPD, and JZ drafted the manuscript; XH, NH, YL, and JZ contributed to manuscript review. All authors read and approved the final manuscript.

**Funding**

This work was supported by grants from the Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research (2017B030301018), Shenzhen, Guangdong, the National Institutes of Health (R01 HL-125128 to YPD), and the Flight Attendant Medical Research Institute (CIA-123062 to YPD).
Availability of data and materials

The data that support the finding of this study are available on request from the corresponding authors.

Declarations

Ethics approval and consent to participate

All animal experiments were conducted in accordance with approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh.

Consent for publication

Not applicable.

Competing interest

All authors declare they have no competing interests.

Author details

1 School of Medicine, Southern University of Science and Technology, No. 1088 Xueyuan Blvd, Nanshan District, Shenzhen 518055, Guangdong, China. 2Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen 518055, Guangdong, China. 3Department of Environmental and Occupational Health, University of Pittsburgh, 100 Technology Dr, Pittsburgh, PA 15261, USA. 4State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. 5Department of Urology & Pathology, University of Michigan, Ann Arbor, MI 48109, USA. 6Department of Urology, University of Pittsburgh, Pittsburgh 15266, USA.

Received: 7 January 2021 Accepted: 16 April 2021
Published online: 21 April 2021

References

1. Miller S. How smoking can hinder fracture healing. Emerg Nurse. 2014;22(4):28–30.
2. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ. 1997;315(7112):841–6.
3. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellemstrøm D, et al. Smoking and fracture risk: a meta-analysis. Osteoporosis Int. 2005;16(2):155–62.
4. Wu ZJ, Zhao P, Liu B, Yuan ZC. Effect of cigarette smoking on risk of hip fracture in men: a meta-analysis of 14 Prospective Cohort Studies. PLoS ONE. 2016;11(11):e0168990.
5. Shen GS, Li Y, Zhao G, Zhou HB, Xie ZG, Xu W, Chen HN, Dong QR, Xu YJ. Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies. Injury. 2015;46(7):1333–40.
6. Tanko LB, Christiansen C. An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause. 2004;11(1):104–9.
7. Strozyk D, Gress TM, Breitling LP. Smoking and bone mineral density: comprehensive analyses of the third National Health and Nutrition Examination Survey (NHANES III). Arch Osteoporos. 2018;13(1):16.
8. Eudy-Byrne R, Gillespie W, Riggs MM, Gastonguay MR. A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis. J Pharmacokinet Pharmacodyn. 2017;44(6):599–609.
9. Houdrup S, Prescott E, Sorensen TJ, Gottschau A, Lauritzen JB, Scholl M, Gronbaek M. Tobacco smoking and risk of hip fracture in men and women. Int J Epidemiol. 2000;29(2):253–9.
10. Haroon M, Khan K, Thong L, Ali K, Janjua F. High prevalence of risk factors for low bone mineral density and estimated fracture and fall risk among elderly medical inpatients: a missed opportunity. Ir J Med Sci. 2019;188(3):531–6.
11. Szulc P, Grammer P, Claustrat B, Marchand F, Duboef F, Delmas PD. Increased bone resorption in moderate smokers with low body weight: the MIMOS study. J Clin Endocrinol Metab. 2002;87(2):666–74.
12. Hermann AP, Brot C, Gram J, Kolthoff N, Mosekilde L. Premenopausal smoking and bone density in 2015 premenopausal women. J Bone Miner Res. 2000;15(4):780–7.
13. Laroche M, Laine Y, Felez A, Moulinier B, Bon E, Cartaurel A, Leophonte P, Mazieres B. Osteocalcin and smoking. Rev Rhum Ed Fr. 1994;61(6):433–4.
14. Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250–61.
15. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423(6937):349–55.
16. Raiz UG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):1318–25.
17. NI X, Xu N, Wang Q. Meta-analysis and systematic review in environmental tobacco smoke risk of female lung cancer by research type. Int J Environ Res Public Health. 2018;15(7):1348.
18. Reumann MK, Schaefer J, Titz B, Aspera-Werz RH, Wong ET, Szostak J, Haussling Y, Ehrent S, Leroy P, Tan WT, et al. E-vapor aerosols do not compromise bone integrity relative to cigarette smoke after 6-month inhalation in an ApoE/-/- mouse model. Arch Toxicol. 2020;94(6):2163–77.
19. Zang J, Dai J, Yao Z, Lu Y, Dougal W, Keller ET. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 2003;63(2):7839–90.
20. Mortaz E, Redegeld FA, Sarir H, Kamali K, Raats D, Nijkamp FP, Folkers G. Cigarette smoke stimulates the production of chemokines in mast cells. J Leukoc Biol. 2008;83(3):578–85.
21. Xiao G, Cui Y, Darcy P, Karsenty G, Franceschi RT. Ascorbic acid-dependent activation of the osteocalcin promoter in MC3T3-E1 preosteoblasts: requirement for collagen matrix synthesis and the presence of an intact OSE2 sequence. Mol Endocrinol. 1997;11(8):1103–13.
22. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. CC2R expression correlates with prostate cancer progression. J Cell Biochem. 2007;101(3):676–85.
23. Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med. 1994;330(6):387–92.
24. Slemenda CW, Hui SL, Longcope C, Johnston CC Jr. Cigarette smoking, obesity, and bone mass. J Bone Miner Res. 1989;4(5):737–41.
25. Hou GQ, Guo C, Song GH, Fang N, Fan WJ, Chen XD, Yuan L, Wang ZQ. Lipopolysaccharide (LPS) promotes osteostimulation and differentiation and activation by enhancing the MAKP pathway and COX-2 expression in RAW264.7 cells. Int J Mol Med. 2013;32(2):503–10.
26. Straberg F, Kassem A, Kasprzykowsky F, Abrahamsson M, Grubb A, Lindholm C, Lerner UH. Inhibition of lipopolysaccharide-induced osteostimulation and bone formation and resorption in vivo and in vitro by cystine proteinase inhibitors. J Leukoc Biol. 2017;101(5):1233–43.
27. Koide N, Kaneda A, Yokochi T, Umezawa K. Inhibition of RANKL- and LPS-induced osteostimulation by novel NF-kappaB inhibitor DTCM-glutarimide. Int Immunopharmacol. 2015;25(1):162–8.
28. Tanaka H, Tanabe N, Shoji M, Suzuki N, Katono T, Sato S, Motohashi M, Maeno M. Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. Life Sci. 2006;78(15):1733–40.
29. Suda K, Udagawa N, Sato N, Takami M, Itoh K, Wu JT, Takahashi N, Nagai K. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteostimulation. J Immunol. 2004;172(4):2504–10.
30. Baud'huin M, Lamoureux F, Duplomb L, Redini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci. 2007;64(18):2334–50.
31. Zhao J, Harper RW, Bachowsky A, Dr YP Identification of multiple MMAP-mediated transcription factors regulated by tobacco smoke in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L480-90.
32. Lee LL, Lee JS, Waldman SD, Casper RF, Grynpas MD. Polycyclic aromatic hydrocarbons present in cigarette smoke cause bone loss in an ovariectomized rat model. Bone. 2002;30(6):917–23.
33. Guttridge DC, Albanese C, Reuther JF, Pestell RG, Baldwin AS Jr. NF- kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19(8):5785–99.
34. Rodu B, Cole P. Tobacco-related mortality. Nature. 1994;370(6486):184.
35. Finette BA, O’Neill JP, Vacek PM, Albertini RJ. Gene mutations with characteristic deletions in cord blood T lymphocytes associated with passive maternal exposure to tobacco smoke. Nat Med. 1998;4(10):1144–51.
36. Zhu S, Haussling V, Aspera-Werz RH, Chen T, Braun B, Weng W, Histing T, Nussler AK. Bisphosphonates reduce smoking-induced osteoporotic-like alterations by regulating RANKL/OPG in an osteoblast and osteoclast co-culture model. Int J Mol Sci. 2020;22(1):53

37. Compton J. Editorial: smoking and the skeleton. J Clin Endocrinol Metab. 2007;92(2):428–9.

38. Ramp WK, Lenz LG, Galvin RJ. Nicotine inhibits collagen synthesis and alkaline phosphatase activity, but stimulates DNA synthesis in osteoblast-like cells. Proc Soc Exp Biol Med. 1991;197(1):36–43.

39. Broulik PD, Jarab J. The effect of chronic nicotine administration on bone mineral content in mice. Horm Metab Res. 1993;25(4):219–21.

40. Akhter MP, Lund AD, Gairola CG. Bone biomechanical property deterioration due to tobacco smoke exposure. Calcif Tissue Int. 2005;77(5):319–26.

41. Blum M, Harris SS, Must A, Phillips SM, Rand WM, Dawson-Hughes B. Household tobacco smoke exposure is negatively associated with premenopausal bone mass. Osteoporos Int. 2002;13(8):663–8.

42. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005;208:126–40.

43. Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF. The effect of cigarette smoking on the bone marrow. Am J Respir Crit Care Med. 1997;155(3):1021–6.

44. Fusby JS, Kassmeier MD, Palmer VL, Perry GA, Anderson DK, Hackfort BT, Alvarez GK, Cullen DM, Akhter MP, Swanson PC. Cigarette smoke-induced effects on bone marrow B-cell subsets and CD4+CD8+ T-cell ratios are reversed by smoking cessation: influence of bone mass on immune cell response to and recovery from smoke exposure. Inhal Toxicol. 2010;22(9):785–96.

45. Rosa RC, Pereira SC, Cardoso FAG, Caetano AG, Santiago HAR, Volpon JB. Second hand tobacco smoke adversely affects the bone of immature rats. Clinics (Sao Paulo). 2017;72(12):785–9.

47. Hirota Y, Hirohata T, Fukuda K, Mori M, Yanagawa H, Ohno Y, Sugioka Y. Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head. Am J Epidemiol. 1993;137(5):530–8.

48. Thomas WR, Holt PG, Keast D. Recovery of immune system after cigarette smoking. Nature. 1974;248(446):358–9.

49. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2(5):372–7.

50. Aspera-Werz RH, Ehnert S, Muller M, Zhu S, Chen T, Weng W, Jacoby J, Nussler AK. Assessment of tobacco heating system 2.4 on osteogenic differentiation of mesenchymal stem cells and primary human osteoblasts compared to conventional cigarettes. World J Stem Cells. 2020;12(8):841–56.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more biomedcentral.com/submissions